<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04079218</url>
  </required_header>
  <id_info>
    <org_study_id>2019-10529</org_study_id>
    <nct_id>NCT04079218</nct_id>
  </id_info>
  <brief_title>Accelerated Genital Tract Aging in HIV: Estradiol Clinical Trial</brief_title>
  <official_title>The Impact of HIV on Accelerated Aging in the Female Genital Tract: a Pilot Trial of Topical Estradiol to Improve the Vaginal Microbiome and Symptoms of Vaginal Atrophy in Menopausal Women With HIV</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Albert Einstein College of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute on Aging (NIA)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>Novo Nordisk A/S</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Albert Einstein College of Medicine</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      During menopause, there is a decrease in a hormone estrogen, which leads to aging of the
      vagina. Vaginal aging includes changes in the type and amount of healthy bacteria in the
      vagina, inflammation and a breakdown of natural barriers that keep the vagina healthy and
      protected from infections. Some menopausal women develop a condition called vaginal atrophy,
      which causes vaginal dryness, irritation, pain with sex, and itching. We are testing whether
      an estradiol tablet placed inside the vagina will lead to fewer changes in the types of
      bacteria present in the vagina, improve vaginal atrophy symptoms and ultimately keep the
      vagina healthier for a longer. This is important for women with HIV as they are living
      longer, healthier, sexually active lives due to successful treatment with antiretrovirals.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      HIV may be associated with premature aging in the female genital tract including alterations
      in the vaginal microbiome and mucosal inflammation, which may increase risk for vaginal
      atrophy, urinary tract infections (UTI) and other genital tract infections. This study will
      determine whether use of vaginal estradiol for 12 weeks in menopausal women living with HIV
      with symptomatic vaginal atrophy will improve atrophy symptoms and the vaginal microbiome and
      reduce mucosal inflammation thereby improving vaginal health. This study will include 50
      participants randomized to treatment with a vaginal estradiol insert or no therapy for 12
      weeks and will have 4 study visits.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">April 15, 2020</start_date>
  <completion_date type="Anticipated">August 31, 2023</completion_date>
  <primary_completion_date type="Anticipated">August 31, 2022</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Participants will be randomly assigned to receive treatment with estradiol vaginal tablets or no treatment.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Vaginal Atrophy Symptoms</measure>
    <time_frame>Between baseline and 6 and 12 weeks</time_frame>
    <description>Change in clinical symptoms measured by most bothersome symptom (MBS) of vaginal atrophy after estradiol treatment</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Vaginal Microbiome</measure>
    <time_frame>Between baseline and 6 and 12 weeks</time_frame>
    <description>Changes in the vaginal microbiome, specifically the relative abundance of protective lactobacillus species L. crispatus as measured by lllumina sequencing and quantities of protective lactobacilli species (L. crispatus, L. jensenii and L. gasseri) as measured by quantitative PCR (qPCR)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Vaginal Microbiome</measure>
    <time_frame>Between baseline and 6 and 12 weeks</time_frame>
    <description>Changes in relative abundance and quantities of bacterial vaginosis associated species</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vaginal cytokines and chemokines</measure>
    <time_frame>Between baseline and 6 and 12 weeks</time_frame>
    <description>Changes in concentrations of cytokines and chemokines in cervicovaginal lavage (CVL)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunoglobulin (Ig)A and IgG coated bacteria</measure>
    <time_frame>Baseline and 6 and 12 weeks</time_frame>
    <description>Differences in levels of live IgA+IgG+ coated, live IgA+IgG- coated, live IgA-IgG-coated and dead bacteria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HIV-1 RNA levels in the genital tract</measure>
    <time_frame>Baseline and 6 and 12 weeks</time_frame>
    <description>HIV-1 RNA testing from cervicovaginal lavage fluid</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>HIV Infection</condition>
  <condition>Vaginal Atrophy</condition>
  <condition>Menopause</condition>
  <condition>Menopause Related Conditions</condition>
  <condition>Aging</condition>
  <condition>Premature Aging</condition>
  <condition>Atrophic Vaginitis</condition>
  <condition>Dysbiosis</condition>
  <condition>Vaginitis</condition>
  <arm_group>
    <arm_group_label>Estradiol Vaginal Insert</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Using a pre-loaded single-use plastic applicator, participants will insert one 10 microgram estradiol tablet intravaginally daily for 2 weeks and then one tablet twice weekly for the remainder of the study for a total of 12 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>No treatment</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>No intervention</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Estradiol Vaginal Insert</intervention_name>
    <description>Using a pre-loaded single-use plastic applicator, participants will insert one 10 microgram estradiol tablet intravaginally daily for 2 weeks and then one tablet twice weekly for the remainder of the study for a total of 12 weeks.</description>
    <arm_group_label>Estradiol Vaginal Insert</arm_group_label>
    <other_name>VagifemÂ®</other_name>
    <other_name>Vagifem (estradiol vaginal tablet)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  HIV infection

          -  Females aged 45-70

          -  Menopause defined by having no menstrual periods for 12 consecutive months, confirmed
             with serum follicle-stimulating hormone (FSH) level &gt;40 IU/ml and serum estradiol
             level &lt;20 pg/ml

          -  Symptomatic vaginal atrophy defined as reporting at least once per week in the past 30
             days, 1 or more of the following symptoms of moderate or severe intensity: Dryness,
             Itching, Irritation, Soreness or pain OR Pain associated with sexual activity at least
             once

          -  Evidence of atrophy on exam, including thin, pale and dry vaginal and vulvar surfaces

          -  Agrees not to use vaginal products other than vaginal estradiol tablet during the
             clinical trial

        Exclusion Criteria:

          -  Current or previous history of breast cancer or estrogen dependent neoplasia

          -  Endometrial hyperplasia or polyps

          -  Current unexplained abnormal genital bleeding

          -  Current or suspected pregnancy

          -  Known current or past thromboembolic disease (deep vein thrombosis or pulmonary
             embolism, not including thrombophlebitis), myocardial infarction or stroke

          -  Known blood clotting disorders including Protein C, Protein S and antithrombin
             deficiency, Factor V Leiden or prothrombin mutations

          -  Hysterectomy

          -  Known severe liver disease

          -  Use of hormones in the 3 months prior to study enrollment

          -  Use of any vaginal or vulvar preparations 1 month prior to enrollment

          -  Antibiotic use in the past 30 days

          -  Abnormal Pap test in the past year

          -  Current acute vaginal infection (diagnosed by wet mount at Visit 1 or 2)

          -  History of adverse reaction to vaginal estradiol

          -  Any serious disease or chronic condition that might interfere with study compliance

          -  Unwilling to agree to the provisions of the protocol
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>45 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kerry J Murphy, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Albert Einstein College of Medicine</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Kerry J Murphy, MD</last_name>
    <phone>718-839-7885</phone>
    <email>kerry.murphy@einstein.yu.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Marla J Keller, MD</last_name>
    <phone>718-430-3240</phone>
    <email>marla.keller@einstein.yu.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Albert Einstein College of Medicine</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10461</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Kerry J Murphy, MD</last_name>
      <phone>718-839-7885</phone>
      <email>kerry.murphy@einstein.yu.edu</email>
    </contact>
    <contact_backup>
      <last_name>Marla J Keller, MD</last_name>
      <phone>718-430-3240</phone>
      <email>marla.keller@einstein.yu.edu</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Murphy K, Keller MJ, Anastos K, Sinclair S, Devlin JC, Shi Q, Hoover DR, Starkman B, McGillick J, Mullis C, Minkoff H, Dominguez-Bello MG, Herold BC. Impact of reproductive aging on the vaginal microbiome and soluble immune mediators in women living with and at-risk for HIV infection. PLoS One. 2019 Apr 26;14(4):e0216049. doi: 10.1371/journal.pone.0216049. eCollection 2019.</citation>
    <PMID>31026271</PMID>
  </reference>
  <reference>
    <citation>Shen J, Song N, Williams CJ, Brown CJ, Yan Z, Xu C, Forney LJ. Effects of low dose estrogen therapy on the vaginal microbiomes of women with atrophic vaginitis. Sci Rep. 2016 Apr 22;6:24380. doi: 10.1038/srep24380. Erratum in: Sci Rep. 2016 Nov 29;6:34119.</citation>
    <PMID>27103314</PMID>
  </reference>
  <reference>
    <citation>Hummelen R, Macklaim JM, Bisanz JE, Hammond JA, McMillan A, Vongsa R, Koenig D, Gloor GB, Reid G. Vaginal microbiome and epithelial gene array in post-menopausal women with moderate to severe dryness. PLoS One. 2011;6(11):e26602. doi: 10.1371/journal.pone.0026602. Epub 2011 Nov 2.</citation>
    <PMID>22073175</PMID>
  </reference>
  <reference>
    <citation>Brotman RM, Shardell MD, Gajer P, Fadrosh D, Chang K, Silver MI, Viscidi RP, Burke AE, Ravel J, Gravitt PE. Association between the vaginal microbiota, menopause status, and signs of vulvovaginal atrophy. Menopause. 2018 Nov;25(11):1321-1330. doi: 10.1097/GME.0000000000001236.</citation>
    <PMID>30358729</PMID>
  </reference>
  <reference>
    <citation>Mitchell CM, Reed SD, Diem S, Larson JC, Newton KM, Ensrud KE, LaCroix AZ, Caan B, Guthrie KA. Efficacy of Vaginal Estradiol or Vaginal Moisturizer vs Placebo for Treating Postmenopausal Vulvovaginal Symptoms: A Randomized Clinical Trial. JAMA Intern Med. 2018 May 1;178(5):681-690. doi: 10.1001/jamainternmed.2018.0116.</citation>
    <PMID>29554173</PMID>
  </reference>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>September 3, 2019</study_first_submitted>
  <study_first_submitted_qc>September 3, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">September 6, 2019</study_first_posted>
  <last_update_submitted>March 12, 2020</last_update_submitted>
  <last_update_submitted_qc>March 12, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 13, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Albert Einstein College of Medicine</investigator_affiliation>
    <investigator_full_name>Kerry Murphy</investigator_full_name>
    <investigator_title>Assistant Professor, Department of Medicine (Infectious Diseases)</investigator_title>
  </responsible_party>
  <keyword>HIV Infection</keyword>
  <keyword>Vaginal Atrophy</keyword>
  <keyword>Menopause</keyword>
  <keyword>Vaginal Microbiome</keyword>
  <keyword>Microbiome</keyword>
  <keyword>Dysbiosis</keyword>
  <keyword>Aging</keyword>
  <keyword>Premature Aging</keyword>
  <keyword>Atrophic Vaginitis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HIV Infections</mesh_term>
    <mesh_term>Vaginitis</mesh_term>
    <mesh_term>Atrophic Vaginitis</mesh_term>
    <mesh_term>Atrophy</mesh_term>
    <mesh_term>Dysbiosis</mesh_term>
    <mesh_term>Aging, Premature</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Estradiol 3-benzoate</mesh_term>
    <mesh_term>Estradiol 17 beta-cypionate</mesh_term>
    <mesh_term>Estradiol</mesh_term>
    <mesh_term>Polyestradiol phosphate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>After publication of the main study findings, external investigators may contact the Principal Investigator Dr. Kerry Murphy for de-identified datasets.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_time_frame>Within 12 months after publication</ipd_time_frame>
    <ipd_access_criteria>De-identified electronic datasets of published results will be made available to external investigators in a format in which subsequent statistical analyses can be performed.</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

